Despite their high sequence homology, the peptide neurotoxins omega-conotoxin MVIIA and MVIIC selectively block N- and P/Q-type calcium channels, respectively. To study the recognition mechanism of calcium channel subtypes, two chimeric analogs of omega-conotoxin MVIIA and MVIIC were synthesized by exchanging their N- and C-terminal halves. Binding assay for both N- and P/Q-type calcium channels showed that amino acid residues restricted to the N-terminal half are important for the recognition of N-type channels, whereas essential residues for P/Q-type channel recognition are widely spread over the whole omega-conotoxin molecule.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0014-5793(97)01056-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Intrathecal Pump Misadventure in Two Acts: An Unrecognized Partial Pocket Fill Followed by an Unusual Withdrawal Syndrome Two Months Later.
J Palliat Med
January 2025
Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
We present a case of a patient with an intrathecal pump who experienced an unrecognized partial pocket fill, leading to an atypical opioid withdrawal characterized by akathisia. A 57-year-old female with multiple myeloma presented to an emergency department with new-onset akathisia requiring admission. Eight weeks prior, her intrathecal pump was refilled with morphine, bupivacaine, and ziconotide.
View Article and Find Full Text PDFC2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models.
J Clin Invest
December 2024
Department of Pharmacology and Therapeutics, College of Pharmacy, University of Florida, Gainesville, United States of America.
Article Synopsis
- - Antagonists like Ziconotide and Gabapentin target CaV2.2 calcium channels to relieve chronic pain, but their clinical use is limited due to issues like narrow therapeutic windows and potential for misuse or side effects.
- - A new compound called C2230 has been identified as a blocker of CaV2.2 channels, showing multiple beneficial effects such as trapping the channel in an inactivated state and specifically targeting pain without affecting other ion channels or motor functions.
- - C2230 effectively reduced pain-like behaviors in various animal models and human neurons, suggesting it could be developed as a new analgesic with a unique binding mechanism that differentiates it from existing treatments.
Ziconotide and psychosis: from a case report to a scoping review.
Front Mol Neurosci
October 2024
TXP Research Group, Universidad Cardenal Herrera-CEU, CEU Universities, Castellón de la Plana, Spain.
Ziconotide is a non-opioid analgesic that acts on N-type voltage-gated calcium channels. Despite its proven effectiveness in pain treatment, it can induce neuropsychiatric symptoms. The aim of this article is to present a case of psychosis secondary to ziconotide and to explore the variety of neuropsychiatric symptoms it produces, exploring the relationship between these symptoms and the mechanism of action of ziconotide.
View Article and Find Full Text PDFBackground: The reported prevalence of neuropathic pain in the general population in Germany is from 6.9% to 10%. There are both medical and surgical treatment options.
View Article and Find Full Text PDFDetermination of related substances in disulfide-rich peptide ziconotide by establishing tandem mass spectrometry methods.
J Pharm Anal
October 2024
Division of Chemical Metrology & Analytical Science, National Institute of Metrology, Beijing, 100029, China.
Image 1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!